Pay in 4 interest-free payments of $6.86 Learn more
Ships within 48 hours · Estimated delivery Sep 29 - Oct 4
As a long-acting peptide, cagrilintide is designed for infrequent dosing schedules in research and clinical protocols, which can improve adherence compared with products that require more frequent administration
Research indicates it reduces pro-inflammatory cytokines like TNF-alpha, IL-6, and IL-1 beta, without broadly suppressing immune function the way corticosteroids do
Clinical trials used doses of 0.3 4.5 mg/week, at a 2.5 mg/ml concentration, a 2.4 mg dose = 0.96 ml = 96 IU on the insulin syringe
Although clinical trials specifically for MASH have not yet been conducted, preclinical studies confirm significant regulatory effects on hepatic metabolism, providing a novel strategy for targeted MASH therapy and supporting future translational research
